Vertex Pharmaceuticals (VRTX) closed at $499.74 on Oct 16, 2026, down 1.8% on the day. The stock is down 3.2% over the past month, up 4.0% over three months, up 10.2% year to date and up 22.5% over the past year. It trades 10.8% below its 52-week high of $560.25 and 24.0% above its 52-week low of $403.16. The close sits below its 50-day moving average ($522.54) and above its 200-day moving average ($475.90).
NextPick tracks VRTX in its Biotech basket alongside MRNA, REGN, BIIB, ALNY and BNTX. As of Oct 16, 2026, the basket's money-flow score is -8 (neutral), and the basket is down 3.4% over five sessions. Over the past month VRTX ranks 6th of 17 basket members by price change.
VRTX is scheduled to report earnings on Nov 2, 2026.
Vertex Pharmaceuticals is scheduled to report on Nov 2, 2026.
Yes — the Oct 16, 2026 close of $499.74 is 5.0% above the 200-day average of $475.90.
VRTX closed 10.8% below its 52-week high of $560.25.
NextPick groups VRTX with MRNA, REGN, BIIB, ALNY and BNTX in its Biotech basket.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
